CA3218103A1 - Autotaxin (atx) inhibitor for the treatment of pancreatic cancer - Google Patents

Autotaxin (atx) inhibitor for the treatment of pancreatic cancer Download PDF

Info

Publication number
CA3218103A1
CA3218103A1 CA3218103A CA3218103A CA3218103A1 CA 3218103 A1 CA3218103 A1 CA 3218103A1 CA 3218103 A CA3218103 A CA 3218103A CA 3218103 A CA3218103 A CA 3218103A CA 3218103 A1 CA3218103 A1 CA 3218103A1
Authority
CA
Canada
Prior art keywords
compound
pancreatic cancer
salt
treatment
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3218103A
Other languages
English (en)
French (fr)
Inventor
Zoe Johnson
Marcel DEKEN
Michael LAHN
Davide MELISI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionctura BV
Original Assignee
Ionctura SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ionctura SA filed Critical Ionctura SA
Publication of CA3218103A1 publication Critical patent/CA3218103A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3218103A 2021-06-09 2022-06-08 Autotaxin (atx) inhibitor for the treatment of pancreatic cancer Pending CA3218103A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2108245.8 2021-06-09
GBGB2108245.8A GB202108245D0 (en) 2021-06-09 2021-06-09 Methods of treatment
PCT/EP2022/065562 WO2022258693A1 (en) 2021-06-09 2022-06-08 Autotaxin (atx) inhibitor for the treatment of pancreatic cancer

Publications (1)

Publication Number Publication Date
CA3218103A1 true CA3218103A1 (en) 2022-12-15

Family

ID=76838834

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3218103A Pending CA3218103A1 (en) 2021-06-09 2022-06-08 Autotaxin (atx) inhibitor for the treatment of pancreatic cancer

Country Status (9)

Country Link
US (1) US20250057820A1 (https=)
EP (1) EP4351563A1 (https=)
JP (1) JP2024522135A (https=)
CN (1) CN117295496A (https=)
AU (1) AU2022290378A1 (https=)
CA (1) CA3218103A1 (https=)
GB (1) GB202108245D0 (https=)
MX (1) MX2023014637A (https=)
WO (1) WO2022258693A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201502020D0 (en) * 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
JP2024511836A (ja) * 2021-03-29 2024-03-15 アイオンクチュラ・ソシエテ・アノニム 膵臓癌の治療のためのｐｉ３ｋ－デルタ阻害剤

Also Published As

Publication number Publication date
CN117295496A (zh) 2023-12-26
GB202108245D0 (en) 2021-07-21
US20250057820A1 (en) 2025-02-20
JP2024522135A (ja) 2024-06-11
EP4351563A1 (en) 2024-04-17
AU2022290378A1 (en) 2024-01-04
MX2023014637A (es) 2024-01-31
WO2022258693A1 (en) 2022-12-15

Similar Documents

Publication Publication Date Title
KR102713072B1 (ko) 두경부암 치료를 위한 egfr 저해제
US20240390401A1 (en) Combination of bcl-2/bcl-xl inhibitors and chemotherapeutic agent and use thereof
US11738003B2 (en) Method for administration
US20160193211A1 (en) Combinations of a btk inhibitor and fluorouracil for treating cancers
CN103533940A (zh) 治疗晚期实体瘤的方法
WO2023092943A1 (zh) 盐酸决奈达隆联合5-氟尿嘧啶在制备抗肿瘤药物中的应用
TW201625243A (zh) 用於治療黑素瘤之藥物組合
US11491168B2 (en) Combination of Bcl-2/Bcl-xL inhibitors and chemotherapeutic agent and use thereof
US20240216385A1 (en) A pi3k-delta inhibitor for the treatment of pancreatic cancer
Nelson et al. Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple‐negative breast cancer
US20250057820A1 (en) Autotaxin (atx) inhibitor for the treatment of pancreatic cancer
KR20140035974A (ko) 종양 질환 치료를 위한 약제 조성물
EP2663318B1 (en) Pharmaceutical composition for treating cancer
CN108503676B (zh) 用于癌症治疗的果糖类似物及其组合物
RU2519199C2 (ru) Противоопухолевый агент, набор и способ лечения рака
GB2502232A (en) Medicine composition containing vitamin D and metformin
RS52668B (sr) Pojačivač antitumornog efekta, antitumorno sredstvo i postupak lečenja kancera
JP2005255643A (ja) 抗腫瘍効果増強方法および抗腫瘍効果増強剤
CN111407748A (zh) 酪醇在制备治疗脑胶质瘤的药物中的应用
WO2024246824A1 (en) Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer
WO2025056747A1 (en) Combination of a wee1 inhibitor and a pkmyt1 inhibitor
US20200085788A1 (en) Method for administration
KR101309036B1 (ko) 방사선 민감도 증진용 약학 조성물
WO2008031358A1 (fr) 1,2-dihydroxy-3-methyl-9,10-anthraquinone utile dans la fabrication de médicaments pour traiter les cancers
Simizu et al. 85 POSTER Inhibition of tumor cell invasion by a heparanase inhibitor and expression of a dominant negative mutant of heparanase

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250513

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250513